The Food and Drug Administration (FDA) and the Therapeutic Goods Administration (TGA), Australia collaborate to plan the development of competencies in regulatory health products for therapeutic purposes. The aim is to ensure that the public in both Thailand and Australia have access to quality and safe products. Dr.Paisarn Dunkum, Secretary-General of the Food and Drug Administration, stated that TGA is responsible for products regulatory for therapeutic purposes, such as medicines, medical devices, herbal products in order to ensure access to quality, safe and effective products.

This meeting, the FDA collaborated with TGA on issues related to the joint action plan in the future, under the Memorandum Of Understanding between the FDA and TGA on the cooperation and collaboration in areas of therapeutic products, in order to encourage the development of collaborating activities relating to the regulation, exchange of information, improvement of the regulatory performance and safety, especially by participating in the Indo-Pacific Regulatory Strengthening Program (RSP) to strengthen the regulatory authorities for ensuring that patients have access to quality and safe products.

In this regard, Dr. Paul Huleatt, Strategic Partnerships and Program Implementation Lead of the International Regulatory Branch, TGA, has invited representatives of the FDA to participate as part of the Mechanism on Substandard and Falsified Medical Products Working Group of the World Health Organization.
 Mr. Michael Wiseman, Assistant Secretary of the International Regulatory Branch, TGA, has expressed support for future cooperation with the FDA and stated that this meeting presents a valuable opportunity to strengthen existing partnerships and enhance the capacity of both organizations. He emphasized that the expertise of both countries in regulating health products will be utilized to foster continued and concrete cooperation in the future.

………………………………………………………………………………………………………………………………….

Publication date February 7, 2023